SOTS 2nd Hour: Eli Lilly Shares Slim Down, Chip on Trump’s Shoulder, Exclusive: ConocoPhillips CEO 8/7/25

Markets React to Tariff Threats, Energy Strategy, and Drug Trial Surprises

The morning news cycle delivered a dense mix of policy moves, corporate strategy, and clinical readouts that together drove choppy trading and shifting investor expectations. A presidential announcement about near‑total tariffs on semiconductors — with narrow exemptions tied to plans to build chips in the United States — created immediate volatility across chip makers, smartphone suppliers and supply‑chain names. At the same time, leaders from major energy companies and the largest public pension fund outlined long‑term positioning in response to commodity cycles and private market opportunities. Meanwhile, a high‑profile drug trial for an oral obesity pill produced results that disappointed investors, underscoring how clinical nuance can translate into big market moves.

Tariff Policy Meets Semiconductor Supply Chains

The administration said it will target semiconductors with up to 100% tariffs unless firms demonstrate they are building production capacity in the U.S., potentially shielding companies that commit to domestic manufacturing or even only the intent to build. That framing immediately raised questions about how exemptions will be applied, since the underlying statute limits company‑specific carve‑outs and instead appears to require product‑level or chip‑by‑chip treatment.

This ambiguity left large parts of the technology supply chain exposed, with Apple and iPhone supply concerns rising and names across the chip ecosystem moving on headlines about potential exemptions. Industry players with announced U.S. investments now look better positioned, but detailed guidance and the exact wording of the tariff rules will determine whether downstream products such as smartphones stay outside the initial measures.

How Tariffs Could Flow Through Prices and Margins

Macro strategists are modeling the effective tariff rate at much higher than headline percentages when combined with other trade measures, with sector‑specific protections potentially increasing costs across goods. Analysts estimate that roughly 60% of tariff costs may be passed to consumers while companies absorb the remaining 40% through margin compression. That split suggests upward pressure on goods‑price inflation and complicates forecasts for central bank policy and the timing of interest‑rate moves.

Energy Sector: Consolidation, Capex, and LNG Infrastructure

ConocoPhillips reported top‑line strength, finalized a major acquisition, and emphasized portfolio rationalization. Management described one‑time and run‑rate synergies from the Marathon Oil deal, asset dispositions to sharpen focus, and a preference for organic investment in high‑quality acreage, LNG projects, and a large Alaska development. The company projects a sizable ramp in free cash flow over the next four years driven by LNG and project execution.

Industry discussion stressed the role of infrastructure and permitting in getting U.S. gas from major basins to export terminals and end markets, especially as decarbonization, AI expansion, and electrification increase power demand. Price signals matter: a sustained move into the $70s per barrel would likely spur U.S. rig activity and boost supply response over time.

Pension Funds Lean Into Private Markets

CalPERS, managing more than a half‑trillion dollars, has increased allocations to private equity and private debt, shifting into mid‑market buyouts and reinstating venture commitments after a strategic review. The fund emphasized manager selection, co‑investment structures, and reduced fee exposure through separately managed accounts. Officials also defended limited public disclosure of private contracts as necessary to preserve negotiating leverage on fees and terms.

Biotech Readout and Investor Expectations

Pharmaceutical markets reacted sharply to a late‑stage readout for an oral obesity pill, where average weight loss fell short of the benchmark set by a competing injectable therapy and discontinuation rates at higher doses raised questions. Although company leadership framed the result as a commercial success for a scalable, oral product, investors focused on efficacy gaps and dropout reasons, driving a double‑digit stock decline that erased substantial market value.

Cross‑Market Themes: Policy, Profitability, and Perception

• Regulatory actions can create immediate re‑rating across entire supply chains when the policy language is broad or ambiguous.
• Large asset managers and pension funds are recalibrating allocations toward private markets to chase returns while actively negotiating lower fees.
• Corporate narrative and headline clinical metrics matter as much as long‑term fundamentals when short‑term investor psychology drives trading.

What This Means for Investors and Stakeholders

In practical terms, companies with announced U.S. manufacturing plans and clear capital allocation stories enjoy relative resilience, while those reliant on globalized supply chains face higher policy risk. Energy firms that can execute on LNG projects and concentrate on high‑margin organic growth will likely outperform in a world of constrained mid‑term supply. Public pension funds that diversify into co‑investments and mid‑market strategies can lower fee drag and potentially capture outsized returns, but their valuation disclosure will remain inherently constrained by private market confidentiality.

These developments together paint a market environment where policy headlines, execution on large capital projects, and clinical nuance are the dominant drivers of near‑term volatility. Investors and plan sponsors should anticipate continued sensitivity to tariff wording, track corporate capital allocation moves, and scrutinize trial dropout and safety data alongside headline efficacy numbers. The morning’s combination of trade policy, energy strategy, pension fund allocation, and clinical data offers a compact case study in how political decisions, operational execution, and scientific outcomes intersect to move global markets.

The day’s coverage distilled into a few central threads: tariff language will shape which manufacturing plans are rewarded, energy companies focused on LNG and disciplined organic growth expect rising cash flow, large pension funds are refining private market strategies to reduce fees and capture return dispersion, and medical trial details can trigger outsized market reactions even when a product meets core design goals.